利妥昔单克隆抗体联合氟达拉滨及环磷酰胺治疗慢性淋巴细胞白血病

Treatment of Chronic Lymphocytic Leukemia with Regimen of Fludarabine,Cyclophosphamide and Rituximab

为了探讨利妥昔单克隆抗体联合氟达拉滨及环磷酰胺(FCR方案)治疗慢性淋巴细胞白血病(CLL)的疗效,采用FCR方案(2-6个疗程)治疗5例CLL患者,其中2例初治、3例复治。FCR方案包括氟达拉滨25mg/m2第2-4天静脉滴注,环磷酰胺250mg/m2第2-4天静脉滴注,利妥昔单克隆抗体375mg/m2第1天静脉滴注,每28天1个疗程。采用多参数流式细胞术检测微小残留病灶(MRD)。结果表明:3例达完全缓解,2例部分缓解;5例中2例MRD检测为阴性。FCR方案的毒副作用主要表现为骨髓抑制和胃肠道反应。结论:FCR方案对CLL的治疗有确切疗效,值得进一步推广使用。

In order to evaluate the effecicney of rituximab combined with fludarabine, cyclophosphamide and rituximab （FCR） regimen for chronic lymphocytic leukemia （CLL）. Five patients with CLL were treated with FCR regimen for 2 -6 courses. FCR regimen included fludarabine 25 mg/m^2 via intraveneous drip at day 2 -4, cyclophosphamide 250 mg/m^2 via intraveneous drip at day 2 -4 and rituximab 375 mg/m^2 via intraveneous drip at day 1. Courses were repeated every 4 weeks. Minimal residu disease （MRD） was determined by multiparametic flow cytometry. The results showed that three patiens achieved complete remission, 2 patients achieved partial remission. MRD was negative in two patiens. In conclusion, FCR is an effective therapeutic regimen for treating CLL patients and is worth to be used in clinic.